Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Mubadala
AddedMar 19, 2024
UpdatedJul 16, 2026
Mubadala

Mubadala

Operating

Global venture capital management with focus on advanced technology investments. Based in Abu Dhabi, San Francisco, and London.

Location
San Francisco, CA, US
Founded
2002
Firm
Compare
Portfolio
Employees
News
Website

Investments

Andalusia Labs
Andalusia Labs

Total Raised

$51.5M

Rounds

2

Series A$48MDecember 2023
Rejuveron Life Sciences
Rejuveron Life Sciences

Total Raised

$97.6M

Rounds

6

Series B$75MSeptember 2023
Georgiamune
Georgiamune

Total Raised

$75M

Rounds

2

Series A$75MAugust 2023
EpiBiologics
EpiBiologics

Total Raised

$73M

Rounds

2

Series A$23MJuly 2023
Series A$50MMarch 2023
Brightspeed
Brightspeed

Total Raised

$512M

Rounds

2

Private Equity$500MMay 2023
Outpace Bio
Outpace Bio

Total Raised

$55M

Rounds

2

Series A$25MMarch 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Truist Insurance Holdings
Truist Insurance Holdings

Total Raised

$1.9B

Rounds

1

Secondary Market$1.9BFebruary 2023
Paradigm
Paradigm

Total Raised

$203M

Rounds

1

Series A$203MJanuary 2023
Precision Neuroscience
Precision Neuroscience

Total Raised

$53M

Rounds

2

Series B$41MJanuary 2023
Resilience
Resilience

Total Raised

$2.5B

Rounds

7

Private EquityJanuary 2023
Vevo Therapeutics
Vevo Therapeutics

Total Raised

$12M

Rounds

1

Seed$12MDecember 2022
UpStream Care
UpStream Care

Total Raised

$185M

Rounds

2

Series B$140MDecember 2022
Juvena Therapeutics
Juvena Therapeutics

Total Raised

$49.2M

Rounds

6

Series A$41MNovember 2022
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Public

Total Raised

$665.4M

Rounds

19

Post Ipo Equity$150MOctober 2022
Alloy Therapeutics
Alloy Therapeutics

Total Raised

$128.3M

Rounds

3

Series D$42MOctober 2022
Pretzel Therapeutics
Pretzel Therapeutics

Total Raised

$72.5M

Rounds

2

Series A$72.5MSeptember 2022
Spotnana
Spotnana

Total Raised

$116M

Rounds

3

Series B$75MJuly 2022
Auron Therapeutics
Auron Therapeutics

Total Raised

$61.4M

Rounds

3

Series A$48MJuly 2022
Flip
Flip

Total Raised

$94.8M

Rounds

4

Series B$60MJuly 2022
Xilis
Xilis

Total Raised

$92M

Rounds

5

Series A$19MJuly 2022
Klarna
Klarna
Public

Total Raised

$4.8B

Rounds

32

Series Unknown$800MJuly 2022
Apex Group
Apex Group

Rounds

3

Private EquityMay 2022
SpotOn
SpotOn

Total Raised

$918M

Rounds

8

Series F$300MMay 2022